|Day's range||12.92 - 13.38|
Ozempic is a drug that has been soaring in popularity over the past year. Three companies that can benefit from the excitement around this weight-loss treatments are Novo Nordisk (NYSE: NVO), Eli Lilly (NYSE: LLY), and WW International (NASDAQ: WW). The biggest benefactor of Ozempic's popularity is likely to be the company that makes the treatment itself: Novo Nordisk.
Three businesses that have not only been around for more than a century but have also been paying dividends going back to the 1800s are Eli Lilly (NYSE: LLY), ExxonMobil (NYSE: XOM), and the Toronto-Dominion Bank (NYSE: TD). Healthcare giant Eli Lilly has been paying a dividend since 1885.
FRANKFURT (Reuters) -German unlisted drugmaker Boehringer Ingelheim said on Wednesday its operating income rose 1.4% in 2022, as more prescriptions of diabetes drug Jardiance trumped higher energy and development costs. Family-owned Boehringer said in its annual report that full-year operating income came in at 4.77 billion euros ($5.17 billion), up from 4.71 billion a year earlier. The Jardiance group of products, managed in a partnership with Eli Lilly, made 5.8 billion euros in sales, a currency-adjusted surge of 39.1%.